NEWS RELEASE

Nevro to Present at the Canaccord Genuity Growth Conference

7/26/2017

REDWOOD CITY, Calif., July 26, 2017 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Wednesday, August 9, 2017 in Boston.

Nevro management is scheduled to present at 1:30 p.m. ET. The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: **http://www.nevro.com/investors**.

Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Investor Relations Contact:

Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com

View original content with multimedia:**http://www.prnewswire.com/news-releases/nevro-to-present-at-the-canaccord-genuity-growth-conference-300494528.html**

SOURCE Nevro Corp.